SG11201705496SA - Bispecific antibodies against cd3 and cd20 - Google Patents

Bispecific antibodies against cd3 and cd20

Info

Publication number
SG11201705496SA
SG11201705496SA SG11201705496SA SG11201705496SA SG11201705496SA SG 11201705496S A SG11201705496S A SG 11201705496SA SG 11201705496S A SG11201705496S A SG 11201705496SA SG 11201705496S A SG11201705496S A SG 11201705496SA SG 11201705496S A SG11201705496S A SG 11201705496SA
Authority
SG
Singapore
Prior art keywords
antibodies against
bispecific antibodies
bispecific
antibodies
Prior art date
Application number
SG11201705496SA
Other languages
English (en)
Inventor
Patrick Engelberts
Esther Breij
Rik Rademaker
Isil Altintas
David Satijn
Sandra Verploegen
Riemke Van Dijkhuizen Radersma
Den Brink Edward Van
Janine Schuurman
Paul Parren
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56355550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201705496S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2015/050276 external-priority patent/WO2015104346A1/en
Application filed by Genmab As filed Critical Genmab As
Publication of SG11201705496SA publication Critical patent/SG11201705496SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
SG11201705496SA 2015-01-08 2016-01-08 Bispecific antibodies against cd3 and cd20 SG11201705496SA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
PCT/EP2015/050276 WO2015104346A1 (en) 2014-01-09 2015-01-08 Humanized or chimeric cd3 antibodies
DKPA201500413 2015-07-15
DKPA201500412 2015-07-15
DKPA201500416 2015-07-16
DKPA201500415 2015-07-16
PCT/EP2016/050296 WO2016110576A1 (en) 2015-01-08 2016-01-08 Bispecific antibodies against cd3 and cd20

Publications (1)

Publication Number Publication Date
SG11201705496SA true SG11201705496SA (en) 2017-08-30

Family

ID=56355550

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201705496SA SG11201705496SA (en) 2015-01-08 2016-01-08 Bispecific antibodies against cd3 and cd20

Country Status (13)

Country Link
US (2) US10544220B2 (enrdf_load_html_response)
EP (1) EP3242682A1 (enrdf_load_html_response)
JP (3) JP6853176B2 (enrdf_load_html_response)
KR (3) KR102712786B1 (enrdf_load_html_response)
CN (2) CN114478792A (enrdf_load_html_response)
AU (3) AU2016205967B2 (enrdf_load_html_response)
CA (1) CA2973159A1 (enrdf_load_html_response)
EA (1) EA201791554A1 (enrdf_load_html_response)
IL (3) IL289946B2 (enrdf_load_html_response)
MX (2) MX391279B (enrdf_load_html_response)
SG (1) SG11201705496SA (enrdf_load_html_response)
UA (1) UA120286C2 (enrdf_load_html_response)
WO (1) WO2016110576A1 (enrdf_load_html_response)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2869845B1 (en) 2012-07-06 2019-08-28 Genmab B.V. Dimeric protein with triple mutations
RS60131B1 (sr) 2013-07-05 2020-05-29 Genmab As Humanizovana ili himerna anti-cd3 antitela
RS60443B1 (sr) 2013-12-17 2020-07-31 Genentech Inc Anti-cd3 antitela i postupci upotrebe
CR20170095A (es) 2014-09-12 2017-07-19 Genentech Inc Anticuerpos anti-cll-1 e inmunoconjugados referencias recíprocas con solicitudes relacionadas
EP3310814B1 (en) 2015-06-16 2023-08-02 F. Hoffmann-La Roche AG Humanized and affinity matured antibodies to fcrh5 and methods of use
EP3310378B1 (en) 2015-06-16 2024-01-24 F. Hoffmann-La Roche AG Anti-cll-1 antibodies and methods of use
JP2018526972A (ja) 2015-06-16 2018-09-20 ジェネンテック， インコーポレイテッド 抗ｃｄ３抗体及び使用方法
AU2016293073B2 (en) 2015-07-15 2022-12-22 Genmab A/S Humanized or chimeric CD3 antibodies
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
EP3252078A1 (en) * 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
WO2018220099A1 (en) * 2017-06-02 2018-12-06 F. Hoffmann-La Roche Ag Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
US11125751B2 (en) 2016-09-30 2021-09-21 Centre National De La Recherche Scientifique Method for isolating HIV reservoir cells expressing CD32a cell marker
TWI791471B (zh) * 2016-11-15 2023-02-11 美商建南德克公司 用於用抗ｃｄ２０/抗ｃｄ３雙特異性抗體進行治療之給藥
EP3559034B1 (en) * 2016-12-20 2020-12-02 H. Hoffnabb-La Roche Ag Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
EP3661555B1 (en) 2017-08-01 2025-04-16 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
KR102758346B1 (ko) 2017-08-04 2025-01-24 젠맵 에이/에스 Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
WO2019034580A1 (en) * 2017-08-14 2019-02-21 Morphosys Ag HUMANIZED ANTIBODIES FOR CD3
CN107501412A (zh) * 2017-10-11 2017-12-22 深圳精准医疗科技有限公司 突变型双特异性抗体及其应用
CA3089287A1 (en) 2018-02-08 2019-08-15 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
SG11202006583VA (en) 2018-02-09 2020-08-28 Genmab As Pharmaceutical compositions comprising bispecific antibodies directed against cd3 and cd20 and their uses
WO2019175658A1 (en) * 2018-03-14 2019-09-19 Novimmune Sa Anti-cd3 epsilon antibodies and methods of use thereof
EP3569617A1 (en) * 2018-05-18 2019-11-20 Trion Research GmbH Pharmaceutical preparation for use in treating epstein- barr virus positive patients with reactivation phenomenon- associated diseases
CN110540593B (zh) * 2018-05-29 2022-05-17 上海药明生物技术有限公司 新型的抗cd3/抗cd20双特异性抗体
US12129298B2 (en) * 2018-06-21 2024-10-29 Daiichi Sankyo Company, Limited Compositions including CD3 antigen binding fragments and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN109836502B (zh) * 2018-11-12 2021-09-07 浙江大学 一种双特异性抗体及其应用
WO2020168555A1 (zh) * 2019-02-22 2020-08-27 武汉友芝友生物制药有限公司 Cd3抗原结合片段及其应用
CN113811770B (zh) * 2019-05-13 2024-06-28 豪夫迈·罗氏有限公司 抑制干扰的药代动力学免疫测定
CN110551221B (zh) * 2019-07-02 2021-03-05 广州爱思迈生物医药科技有限公司 一种双特异性抗体及其制备方法与应用
MX2022001721A (es) * 2019-08-15 2022-03-11 Genmab As Composiciones farmaceuticas que comprenden anticuerpos biespecificos dirigidos contra cd3 y cd20 y sus usos.
CN111100204B (zh) * 2019-11-26 2022-03-11 山东立菲生物产业有限公司 靶向cd20的抗体、其制备方法和应用
WO2021119505A1 (en) 2019-12-13 2021-06-17 Genentech, Inc. Anti-ly6g6d antibodies and methods of use
WO2021144315A1 (en) * 2020-01-13 2021-07-22 Synaffix B.V. Conjugates of antibodies an immune cell engagers
CN113402612A (zh) * 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
TW202200624A (zh) 2020-03-18 2022-01-01 丹麥商珍美寶股份有限公司 抗體
US20230227570A1 (en) 2020-05-08 2023-07-20 Genmab A/S Bispecific antibodies against cd3 and cd20
US10981996B1 (en) 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US11976120B2 (en) * 2020-06-01 2024-05-07 Boehringer Ingelheim International Gmbh Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
CN112062855B (zh) * 2020-08-26 2024-08-30 北京天诺健成医药科技有限公司 一种含有衔接器的药物治疗剂的开发和应用
MX2023002542A (es) 2020-09-10 2023-03-15 Genmab As Anticuerpo biespecifico contra cumulo de difirenciacion 3 (cd3) y cumulo de difirenciacion 20 (cd20) en terapia combinada para el tratamiento del linfoma difuso de celulas b grandes.
CA3190349A1 (en) 2020-09-10 2022-03-17 Brian Elliott Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia
BR112023004321A2 (pt) 2020-09-10 2023-04-04 Genmab As Método para tratar linfoma de célula b grande difusa em um sujeito humano
IL301086A (en) 2020-09-10 2023-05-01 Genmab As Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
US20230312759A1 (en) * 2020-09-10 2023-10-05 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
AU2021341509A1 (en) 2020-09-10 2023-04-13 Genmab A/S Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma
US12351643B2 (en) 2020-11-04 2025-07-08 Genentech, Inc. Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
CN114656562B (zh) * 2020-12-23 2023-11-03 北京天广实生物技术股份有限公司 结合人和猴cd3的抗体及其应用
US12274747B2 (en) 2021-01-28 2025-04-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
US20240139322A1 (en) * 2021-03-10 2024-05-02 H. Lee Moffitt Cancer Center And Research Institute Inc. Compositions and methods to reduce therapeutic t cell toxicity
IL305636A (en) * 2021-03-12 2023-11-01 Genmab As Variants of non-activating antibodies
CN117321078A (zh) 2021-04-30 2023-12-29 豪夫迈·罗氏有限公司 针对用抗cd20/抗cd3双特异性抗体和抗cd79b抗体药物缀合物进行组合治疗的给药
WO2022241235A1 (en) 2021-05-14 2022-11-17 Genentech, Inc. Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
US20230241211A1 (en) 2022-01-28 2023-08-03 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
US20230303693A1 (en) 2022-01-28 2023-09-28 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
IL316002A (en) 2022-04-11 2024-11-01 Regeneron Pharma Compositions and methods for universal tumor cell killing
WO2023198839A2 (en) 2022-04-13 2023-10-19 Genmab A/S Bispecific antibodies against cd3 and cd20
TW202519266A (zh) 2022-04-13 2025-05-16 美商建南德克公司 莫蘇妥珠單抗之醫藥組成物及其使用方法
WO2024102948A1 (en) 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
AU2023398887A1 (en) * 2022-12-14 2025-06-26 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules and methods of use thereof
WO2024173830A2 (en) 2023-02-17 2024-08-22 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies
WO2024206884A1 (en) 2023-03-31 2024-10-03 AbelZeta Inc. Bispecific chimeric antigen receptors targeting cd20 and bcma
AU2024255174A1 (en) 2023-04-13 2025-10-09 Genmab A/S Methods of treating lymphoma with bispecific antibodies against cd3 and cd20
WO2024236035A1 (en) 2023-05-15 2024-11-21 Genmab A/S Methods of treating cd20 expressing b-cell cancers
US20240400685A1 (en) 2023-05-15 2024-12-05 Genmab A/S Highly purified epcoritamab compositions
WO2025064890A1 (en) * 2023-09-20 2025-03-27 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules targeting cd180 and cd3 and methods of use thereof
WO2025109119A1 (en) * 2023-11-22 2025-05-30 Priothera Sas Methods of treatment with multispecific antigen-binding proteins in combination with s1p receptor modulators

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110140142A (ko) * 2002-10-17 2011-12-30 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
CA2625440C (en) 2005-10-11 2023-06-13 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof
EP2155790A1 (en) * 2007-05-31 2010-02-24 Genmab A/S Method for extending the half-life of exogenous or endogenous soluble molecules
AU2008255350B2 (en) 2007-05-31 2014-07-10 Genmab A/S Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals
CA2689895A1 (en) 2007-05-31 2008-12-04 Genmab A/S Non-glycosylated recombinant monovalent antibodies
WO2010037838A2 (en) * 2008-10-01 2010-04-08 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
TW201109438A (en) 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EA022984B1 (ru) 2009-12-29 2016-04-29 Эмерджент Продакт Дивелопмент Сиэтл, Ллс Конструкты, связывающиеся с ron, и способы их использования
KR101930964B1 (ko) * 2010-04-20 2018-12-19 젠맵 에이/에스 이종이량체 항체 ｆｃ-함유 단백질 및 그의 생산 방법
KR20240025059A (ko) * 2010-11-30 2024-02-26 추가이 세이야쿠 가부시키가이샤 세포상해 유도 치료제
CA2832389A1 (en) * 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
NZ703939A (en) * 2011-05-21 2016-01-29 Macrogenics Inc Cd3-binding molecules capable of binding to human and non-human cd3
SI2748201T1 (en) 2011-08-23 2018-03-30 Roche Glycart Ag Bispecific antigen-binding molecules that activate T-cells
EP2869845B1 (en) 2012-07-06 2019-08-28 Genmab B.V. Dimeric protein with triple mutations
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
EP2961773B1 (en) 2013-02-26 2019-03-20 Roche Glycart AG Bispecific t cell activating antigen binding molecules
JP2016512421A (ja) 2013-02-26 2016-04-28 ロシュ グリクアート アーゲー 二重特異性ｔ細胞活性化抗原結合分子
RS60131B1 (sr) 2013-07-05 2020-05-29 Genmab As Humanizovana ili himerna anti-cd3 antitela
JP2016531100A (ja) * 2013-07-12 2016-10-06 ザイムワークス，インコーポレイテッド 二重特異的なｃｄ３及びｃｄ１９抗原結合構築物
RS60443B1 (sr) * 2013-12-17 2020-07-31 Genentech Inc Anti-cd3 antitela i postupci upotrebe
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
SI3699198T1 (sl) 2014-11-17 2025-06-30 Regeneron Pharmaceuticals, Inc. Postopki zdravljenja tumorja z uporabo bispecifičnega protitelesa CD3XCD20
EP3464370A1 (en) 2016-06-01 2019-04-10 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma
WO2019034580A1 (en) * 2017-08-14 2019-02-21 Morphosys Ag HUMANIZED ANTIBODIES FOR CD3
AU2021341509A1 (en) * 2020-09-10 2023-04-13 Genmab A/S Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma

Also Published As

Publication number Publication date
AU2022200871B2 (en) 2025-05-08
JP2018508188A (ja) 2018-03-29
IL253166A0 (en) 2017-08-31
JP7596342B2 (ja) 2024-12-09
CN114478792A (zh) 2022-05-13
IL318350A (en) 2025-03-01
KR102663073B1 (ko) 2024-05-07
MX2017008875A (es) 2017-09-27
MX391279B (es) 2025-03-21
NZ733531A (en) 2024-11-29
EA201791554A1 (ru) 2017-12-29
JP2023002615A (ja) 2023-01-10
BR112017014551A2 (pt) 2018-05-15
JP7177317B2 (ja) 2022-11-24
CN107660214A (zh) 2018-02-02
US20170355767A1 (en) 2017-12-14
IL289946B1 (en) 2025-02-01
JP2021104020A (ja) 2021-07-26
MX2022004082A (es) 2022-05-03
EP3242682A1 (en) 2017-11-15
IL253166B (en) 2022-02-01
UA120286C2 (uk) 2019-11-11
AU2016205967A1 (en) 2017-07-27
KR20240148942A (ko) 2024-10-11
US20200199231A1 (en) 2020-06-25
CN107660214B (zh) 2022-02-08
IL289946B2 (en) 2025-06-01
KR102712786B1 (ko) 2024-10-04
CA2973159A1 (en) 2016-07-14
AU2016205967B2 (en) 2021-11-11
AU2022200871A1 (en) 2022-03-03
AU2025213616A1 (en) 2025-08-21
WO2016110576A1 (en) 2016-07-14
KR20240064746A (ko) 2024-05-13
KR20170128222A (ko) 2017-11-22
IL289946A (en) 2022-03-01
US10544220B2 (en) 2020-01-28
JP6853176B2 (ja) 2021-03-31

Similar Documents

Publication Publication Date Title
IL289946A (en) Bispecific antibodies against cd3 and cd20
ZA202006983B (en) Bispecific antibody constructs binding dll3 and cd3
ZA201801673B (en) Optimized anti¿cd3 bispecific antibodies and uses thereof
PL3519437T3 (pl) Przeciwciała dwuswoiste przeciwko p95HER2
IL255076A0 (en) Bispecific antibody constructs for cdh3 and cd3
RS62332B1 (sr) Heterodimerna antitela koja vezuju cd3 i cd20
SG10202000828TA (en) Bispecific antibody constructs binding mesothelin and cd3
PL3328888T3 (pl) Przeciwciała anty-psma, dwuswoiste cząsteczki wiążące antygen, które wiążą psma i cd3 oraz ich zastosowania
SG11201705252UA (en) Anti-pd-1 monoclonal antibodies and obtaining method thereof
LT3328892T (lt) Bispecifinio antikūno konstruktai, surišantys egfrviii ir cd3
GB201710838D0 (en) Bispecific antibodies
EP3661555C0 (en) BISPECIFIC ANTIBODIES AND THEIR USES
IL269577B (en) Bispecific antibodies anti–pd–l1–anti–tim–3